glp-1 agonist and heart failure receptor agonists (GLP-1RAs): cardiovascular actions therapeutic potential Glucagon-like peptide 1(GLP-1) receptor agonists
Description
Why are GLP-1 agonists suddenly everywhere in obesity treatment
Obesity Drug Market Overview and Growth Potential The US obesity drug market is on a meteoric rise, projected to soar past USD 73 billion by 2034
May 21, 2024
Hyperinsulinemia and ectopic lipid accumulation promote activation of pro-inflammatory pathways, including Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-B) signaling and NLRP3 inflammasome activation, which in turn exacerbate loss of immune tolerance [52,53]
